Survodutide SURV

An experimental injectable weight-loss and liver-health drug from a major drug company, in human trials for obesity and a serious liver disease. Trial data show real weight loss and improved liver health, though it remains unapproved pending more results.

Also known as BI 456906

Effects Lose fat

Routes Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial doses being finalized

Reported range Phase III trials: up to 6 mg once weekly, titrated

Route Subcutaneous injection

Frequency Once weekly

Duration Trial durations of up to 1-2 years

A GLP-1/glucagon dual agonist (Boehringer Ingelheim/Zealand Pharma) in late-stage trials for obesity and MASH; not FDA-approved as of this writing, so any current supply is unregulated.

Where this comes from Published Phase III clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.